Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Stroke. 2016 Nov 1;47(12):2979–2985. doi: 10.1161/STROKEAHA.116.013881

Table Three. Intra-arterial Trial Results Relevant to Neuroprotection.

Recanalization is predicted to improve the odds of success in a neuroprotectant clinical stroke trial. The outcomes of most relevance in designing selection criteria for a neuroprotection trial are rates of successful reperfusion, eventual disability (mRS), symptomatic ICH, and mortality. Although trials reported successful recanalization at different times, we looked for “late” recanalization meaning sometime after the immediate treatment period, typically 24 hours following IAT.

Trial Late Recanalization or
Reperfusion (%)
IA vs. Control		 mRS 0–2
IA vs. Control		 sICH (%)
IA vs. Control		 Mortality
IA vs. Control
ESCAPE 72.4§\31.2 53\29.3 3.6\2.7 10.4\19.0
EXTEND-IA 89♯\34♯
(86*\not reported)		 71\40 0\6 9\20
MR CLEAN 84\57.5
(58.7*\Not Reported)		 32.6\19.1 7.7\6.4 21\22
REVASCAT 66*\Not Reported 43.7\28.2 1.9\1.9 18.4\15.5
SWIFT PRIME 83§§\40§§ 60\35 0\3 9\12
*

Defined as achieving the modified TICI 2b/329

§

: Defined as achieving TICI score29 of 2b/3.

: Defined as achieving mAOL score of 2 or 330.

#

: Defined as reperfusion >90% without sICH.

§§

: Defined as reperfusion ≥90%.